Indaptus Therapeutics (INDP) Competitors $0.34 -0.01 (-1.68%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock INDP vs. SXTC, OVID, NAII, SLGL, BIVI, CGTX, CMMB, ASBP, LGVN, and ELEVShould you be buying Indaptus Therapeutics stock or one of its competitors? The main competitors of Indaptus Therapeutics include China SXT Pharmaceuticals (SXTC), Ovid Therapeutics (OVID), Natural Alternatives International (NAII), Sol-Gel Technologies (SLGL), BioVie (BIVI), Cognition Therapeutics (CGTX), Chemomab Therapeutics (CMMB), Aspire Biopharma (ASBP), Longeveron (LGVN), and Elevation Oncology (ELEV). These companies are all part of the "pharmaceutical products" industry. Indaptus Therapeutics vs. Its Competitors China SXT Pharmaceuticals Ovid Therapeutics Natural Alternatives International Sol-Gel Technologies BioVie Cognition Therapeutics Chemomab Therapeutics Aspire Biopharma Longeveron Elevation Oncology China SXT Pharmaceuticals (NASDAQ:SXTC) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk, earnings and community ranking. Which has stronger earnings and valuation, SXTC or INDP? China SXT Pharmaceuticals has higher revenue and earnings than Indaptus Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChina SXT Pharmaceuticals$1.82M17.76-$3.10MN/AN/AIndaptus TherapeuticsN/AN/A-$15.42M-$1.49-0.23 Do analysts rate SXTC or INDP? Indaptus Therapeutics has a consensus target price of $8.50, indicating a potential upside of 2,406.64%. Given Indaptus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Indaptus Therapeutics is more favorable than China SXT Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China SXT Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Indaptus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in SXTC or INDP? 5.0% of China SXT Pharmaceuticals shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 4.0% of China SXT Pharmaceuticals shares are held by insiders. Comparatively, 20.6% of Indaptus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, SXTC or INDP? China SXT Pharmaceuticals has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Indaptus Therapeutics has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Does the media prefer SXTC or INDP? In the previous week, China SXT Pharmaceuticals and China SXT Pharmaceuticals both had 2 articles in the media. Indaptus Therapeutics' average media sentiment score of 0.43 beat China SXT Pharmaceuticals' score of 0.29 indicating that Indaptus Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment China SXT Pharmaceuticals Neutral Indaptus Therapeutics Neutral Does the MarketBeat Community favor SXTC or INDP? China SXT Pharmaceuticals received 69 more outperform votes than Indaptus Therapeutics when rated by MarketBeat users. However, 86.67% of users gave Indaptus Therapeutics an outperform vote while only 61.65% of users gave China SXT Pharmaceuticals an outperform vote. CompanyUnderperformOutperformChina SXT PharmaceuticalsOutperform Votes8261.65% Underperform Votes5138.35% Indaptus TherapeuticsOutperform Votes1386.67% Underperform Votes213.33% Is SXTC or INDP more profitable? China SXT Pharmaceuticals' return on equity of 0.00% beat Indaptus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets China SXT PharmaceuticalsN/A N/A N/A Indaptus Therapeutics N/A -177.27%-141.06% SummaryIndaptus Therapeutics beats China SXT Pharmaceuticals on 8 of the 13 factors compared between the two stocks. Get Indaptus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INDP vs. The Competition Export to ExcelMetricIndaptus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.44M$6.94B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-0.208.7927.2619.97Price / SalesN/A263.06412.06157.64Price / CashN/A65.8538.2534.64Price / Book0.246.597.064.69Net Income-$15.42M$144.20M$3.24B$248.14M7 Day Performance-2.25%3.81%2.56%2.39%1 Month Performance-18.54%11.10%8.75%6.06%1 Year Performance-85.99%3.95%31.30%13.57% Indaptus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INDPIndaptus Therapeutics2.8945 of 5 stars$0.34-1.7%$8.50+2,406.6%-86.1%$5.44MN/A-0.206Short Interest ↑Gap DownSXTCChina SXT Pharmaceuticals0.4897 of 5 stars$1.32-5.0%N/A-77.6%$20.89M$1.82M0.0090Short Interest ↑Gap DownOVIDOvid Therapeutics4.3753 of 5 stars$0.29+6.5%$2.78+860.1%-89.7%$20.62M$548K-0.6260News CoverageNAIINatural Alternatives International0.7815 of 5 stars$3.31-0.4%N/A-48.0%$20.43M$125.48M-2.56290News CoveragePositive NewsShort Interest ↑SLGLSol-Gel Technologies2.7476 of 5 stars$7.32+1.5%$40.00+446.7%-7.7%$20.38M$12.10M-21.5250Short Interest ↓BIVIBioVie2.4796 of 5 stars$1.07+2.9%$3.00+180.4%+124.3%$19.86MN/A-0.1110CGTXCognition Therapeutics3.6664 of 5 stars$0.32+32.6%$5.63+1,674.4%-84.7%$19.65MN/A-0.3320Positive NewsShort Interest ↓High Trading VolumeCMMBChemomab Therapeutics3.6046 of 5 stars$1.35+2.3%$8.50+529.6%+20.3%$19.39MN/A-1.3520News CoveragePositive NewsASBPAspire BiopharmaN/A$0.39-10.5%N/AN/A$19.07MN/A0.00N/ANews CoverageLGVNLongeveron3.5316 of 5 stars$1.25+0.8%$8.67+593.3%+65.9%$18.66M$2.23M-0.2020News CoverageGap DownELEVElevation Oncology3.3974 of 5 stars$0.31+3.7%$3.39+987.6%-88.9%$18.44MN/A-0.3840Trending NewsAnalyst DowngradeShort Interest ↓Analyst Revision Related Companies and Tools Related Companies SXTC Alternatives OVID Alternatives NAII Alternatives SLGL Alternatives BIVI Alternatives CGTX Alternatives CMMB Alternatives ASBP Alternatives LGVN Alternatives ELEV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INDP) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indaptus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Indaptus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INDP Stock Free INDP Stock Alerts